Targeted binding agents directed to cd105 and uses thereof

An antibody and monoclonal antibody technology, applied in the direction of antibodies, specific peptides, anti-tumor drugs, etc., can solve the problems of embryonic lethality, failure to develop, and poor correlation of vascular smooth muscle cells.

Inactive Publication Date: 2012-03-21
MEDIMMUNE LLC
View PDF143 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In a transgenic rodent model of hereditary hemorrhagic telangiectasia with a heterozygous genotype for CD105 (CD105+ / -), mice exhibited no Regular, dilated and thin-walled vessels with poor association with vascular smooth muscle cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeted binding agents directed to cd105 and uses thereof
  • Targeted binding agents directed to cd105 and uses thereof
  • Targeted binding agents directed to cd105 and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0322] Antibody preparation

[0323] As described in this article, by using XenoMouse techniques (described in detail below) to prepare antibodies. Such mice are capable of producing human immunoglobulin molecules and antibodies and are defective in the production of murine immunoglobulin molecules and antibodies. Techniques used to achieve the above results are disclosed in the patents, applications and references disclosed in the Background section herein. In particular, however, preferred embodiments of the transgenic production of mice and resulting antibodies are described in U.S. Patent Application Serial No. 08 / 759,620, filed December 3, 1996, International Patent Application No. Published June 11, 1998. It is described in WO 98 / 24893 and WO 00 / 76310 published December 21, 2000, the disclosures of which are incorporated herein by reference. Also, see Mendez et al. Nature Genetics 15:146-156 (1997), the disclosure of which is incorporated herein by reference.

[0...

Embodiment 1

[0384] Immunity and titer

[0385] Cells and Transfection

[0386] The mouse pre-B cell line B300-19 was cultured in RPMI 1640 medium containing 10% fetal bovine serum, 50 μM 2-mercaptoethanol, 100 U / ml penicillin and 100 μg / ml streptomycin. HEK 293F cells were grown in DMEM / F12 (50 / 50 mixture) medium supplemented with 10% FBS, 2 mM L-glutamine, 50 μM BME, 100 units of penicillin-g / ml, 100 units of MCG-streptomycin / ml. Human CD105 expression plasmids were transfected into HEK 293F or B300.19 cells using LipofectAMINE 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Transfection was performed for 48 hours followed by selection for two weeks using 1 mg / ml G418 (Invitrogen, Carlsbad, CA). Stable G418 resistant clones were stained with primary mouse anti-human CD105 monoclonal antibody and analyzed by FACS. B300.19 stable transfectants were used for immunization, while HEK293F stable transfectants were used for screening.

[0387] imm...

Embodiment 2

[0398] Recovery of lymphocytes, isolation of B cells, fusion and generation of hybridoma cells

[0399] Immunized mice were sacrificed by cervical dislocation, draining lymph nodes were harvested, and cohorts were pooled. This process performs four fetches.

[0400] Lymphocytes were dissociated by trituration in DMEM to release the cells from the tissue, and the cells were suspended in DMEM. The cells were counted and 0.9 ml DMEM / 100 million lymphocytes were added to the spheroid to allow gentle and complete resuspension of the cells. The cells were labeled using 100 μl CD90+ magnetic beads per 100 million cells by incubating with the magnetic beads for 15 minutes at 4°C. will contain up to 10 8 (or the total number of cells up to 2X10 9 ) The magnetically labeled cell suspension of positive cells was loaded onto the LS+ column, and the column was washed with DMEM. The total effluent was collected as a CD90 negative fraction (the majority of these cells are expected to be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and / or overproduction of CD105 and as diagnostics.

Description

technical field [0001] The present invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the present invention relates to fully human monoclonal antibodies directed against CD105. The targeted binding agents are useful in the treatment of diseases associated with CD105 activity and / or overproduction, and as diagnostic tools. Background technique [0002] CD105, or endoglin, is a transmembrane glycoprotein expressed on activated vascular endothelial cells (Letamendia A, Lastres P, Botella LM, et al. J Biol Chem 1998; 273:33011-9). CD105 has also been reported to be highly expressed on tumor blood vessels and to a lesser extent on a limited number of other cell types including macrophages, fibroblasts and syncytiotrophoblasts (Fonsatti E et al., Oncogene 2003:22:6557 -6563). [0003] CD105 is composed of two disulfide bonded subunits, both 95 kDa, forming a 180-kDa homodimeric protein (Barbara NP, Wrana JL, Letarte M. J Biol ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395
CPCC07K2317/92C07K2317/565C07K16/2896C07K2317/73A61K2039/505A61P35/00A61K39/395C07K16/28C12N15/11
Inventor J·巴布科克S·T·巴里G·加西特-伯恩斯坦N·莱恩Q·周
Owner MEDIMMUNE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap